β-Cyclodextrin derivatives

Details β-Cyclodextrin derivatives β-Cyclodextrin derivatives

2005-01-28

2010-12-14

Zeman, Robert A (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S375000

Reexamination Certificate

active

07851457

ABSTRACT:
The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of β-cyclodextrin. Per-substituted alkylamino derivates displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition of one of the alkylamino derivatives to the bilayer lipid membrane with multiple PA channels caused a significant decrease in membrane conductance. Thus, the invention also provides methods for protection against anthrax toxicity.

REFERENCES:
patent: 4247535 (1981-01-01), Lewis et al.
patent: 4258180 (1981-03-01), Lewis et al.
patent: 4537717 (1985-08-01), Abbott et al.
patent: 5250520 (1993-10-01), Kurita et al.
patent: 5585216 (1996-12-01), Baur et al.
patent: 5599912 (1997-02-01), Rodell et al.
patent: 5728823 (1998-03-01), Reuscher et al.
patent: 5739121 (1998-04-01), Wiebe et al.
patent: 5760017 (1998-06-01), Djedaini-Pilard et al.
patent: 5800602 (1998-09-01), Baur et al.
patent: 5821349 (1998-10-01), Djedaini-Pilard et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5959089 (1999-09-01), Hanessian et al.
patent: 6042723 (2000-03-01), Duval et al.
patent: 6337385 (2002-01-01), Muir et al.
patent: 6444703 (2002-09-01), Kamoda et al.
patent: 6632748 (2003-10-01), Yim et al.
patent: 6716827 (2004-04-01), Roselli et al.
patent: 6858723 (2005-02-01), Auzely-Velty et al.
patent: 7169477 (2007-01-01), Lyu et al.
patent: 2003/0050296 (2003-03-01), Bommer et al.
patent: 2004/0116385 (2004-06-01), Vicente et al.
patent: 2005/0059634 (2005-03-01), Venton et al.
patent: 2006/0199785 (2006-09-01), Fahmi et al.
patent: 2006/0247208 (2006-11-01), Karginov et al.
patent: 2007/0021380 (2007-01-01), Wiebe et al.
patent: 2008/0234182 (2008-09-01), Karginov
patent: 2009/0005343 (2009-01-01), Hecht et al.
patent: 2425663 (1975-12-01), None
patent: 3710569 (1987-03-01), None
patent: 4136325 (1993-05-01), None
patent: 19520967 (1996-12-01), None
patent: 19520989 (1996-12-01), None
patent: 0447171 (1991-09-01), None
patent: 1245628 (2002-10-01), None
patent: 2053399 (1994-07-01), None
patent: 2669535 (1992-05-01), None
patent: 2839313 (2003-11-01), None
patent: 2878853 (2006-06-01), None
patent: 2261740 (1993-05-01), None
patent: 49085015 (1974-08-01), None
patent: 50140476 (1975-11-01), None
patent: 51142088 (1976-12-01), None
patent: 52138580 (1977-11-01), None
patent: 53049089 (1978-05-01), None
patent: 03075634 (1991-03-01), None
patent: 06065307 (1994-03-01), None
patent: 06136004 (1994-05-01), None
patent: 10060006 (1998-03-01), None
patent: 2005290066 (2005-10-01), None
patent: WO 9422455 (1994-10-01), None
patent: WO9517191 (1995-06-01), None
patent: WO97/31628 (1997-09-01), None
patent: WO97/49735 (1997-12-01), None
patent: WO9749735 (1997-12-01), None
patent: WO9950307 (1999-10-01), None
patent: WO01/040316 (2001-06-01), None
patent: WO01/083564 (2001-11-01), None
patent: WO01/98370 (2001-12-01), None
patent: WO02/077000 (2002-10-01), None
patent: WO03/093300 (2003-11-01), None
patent: WO2004/014959 (2004-02-01), None
patent: WO2004/085487 (2004-10-01), None
patent: WO2004/087768 (2004-10-01), None
patent: WO2005/042590 (2005-04-01), None
patent: WO2006/001844 (2006-01-01), None
patent: WO2006/027631 (2006-03-01), None
patent: WO2006/075580 (2006-07-01), None
Tamagaki et al. (Journal of the Chemical Society, Perkin Transacations 2: Physical Organic Chemistry, 1995 vol. 2, pp. 389-393).
Bidan et al. (Biosensors and Bioelectronics, 1994, vol. 9, pp. 219-229).
Hamelin et al. (Journal of Physicial Chemistry, 1995, vol. 99(51), pp. 17877-17885).
Bondarenko et al. (Analytical Chemistry, 1998 vol. 70 No. 14, pp. 3042-3045).
Tsujihara et al. (Chemistry Letters, 1978, vol. 12, pp. 1333).
Ng et al. (Journal of Chromatography A, 2002, vol. 968 pp. 31-40).
Stoeckel et al. Inclusion complexes of flavonoids into natrual and chemically modified B-cyclodextrans. Colloques- Institut National de la Recherche Agronomique (1995), 69 (Polyphenols 94), 191-192.
Dixon et al., “Anthrax”, N. Engl. J. Med., 341(11):815-826 (1999).
Brossier et al., “Toxins ofBacillus anthracis”, Toxicon, 39:1747-1755 (2001).
Petosa et al., “Crystal Structure of the Anthrax Toxin Protective Antigen”, Nature, 385:833-838 (1997).
Karginov et al., “Treatment of Anthrax Infection With Combination of Ciproflaxacin and Antibodies to Protective Antigen ofBacillus anthracis”, FEMS Immun. Med. Microb., 40:71-74 (2004).
Baer et al., “Improved Preparation of Hexakis(6-deoxy)cyclomaltohexaose and Heptakis(6-deoxy)cyclomaltoheptaose”, Carbohydr. Res., 228:307-314 (1992).
Vizitiu et al., “Synthesis of Monofacially Functionalized Cyclodextrins Bearing Amino Pendent Groups”, J. Org. Chem., 62:8760-8766 (1997).
Iwata et al., “Manufacture of Cyclodextrin Derivatives”, Jpn. Kokai Tokkyo Koho, 9pp., (1989).
Minora et al., “Amino Acid Polymers Containing Cyclodextrin in the Main Chain and their Preparation” Jpn. Kokai Tokkyo Koho 5pp., (1994).
Fukuhara et al., “Synthesis and characterization of the first pair of an unlocked and a locked self-inclusion complex from a permethylated alpha-cyclodextrin derivative”, Chem. Letters 32(6):536-537 (2003).
Kurita et al., “Cyclodextrin Derivatives”, Jpn. Kokai 7pp (1974).
Karginov et al., “Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities”; Antimicrobial Agents and Chemotherapy (2006), 50(11),3740-3753.
Wang et al., “Per-6-substituted-per-6-deoxy-β-cyclodextrins Inhibit the Formation of β-Amyloid Peptide Derived Soluble Oligomers”; Journal of Medicinal Chemistry (2004), 47(13),3329 -3333.
Croft et al., “Synthesis of Chemically Modified Cyclodextrins”, Tetrahedron, 39(9):1417-1474 (1983).
Castro-Hermida et al., “Treatment With B-Cyclodextrin of Natural Cryptosporidium Parvum Infections in Lambs Under Field Conditions”, International Journal for Parasitology, 21:1134-1137 (2001).
Salem et al., “Efficacies of Cyclodextrin-Complexed and Liposome-Encapsulated Clarithromycin Against Mycobacterium Avium Complex Infection in Human Macrophages”, International Journal of Pharmaceutics, 250:403-414 (2003).
Karginov et al., “β-Cyclodextrin derivatives that inhibit anthrax lethal toxin”; Bioorganic & Medicinal Chemistry, 14(1), 33-40 (2006).
Hoogenboom et al. “Synthesis of star-shaped poly(.vepsiln.-caprolactone) via ‘click’ chemistry and ‘supramolecular click’ chemistry”; Chemical Communications (Cambridge, United Kingdom) (38), 4010-4012 (2006).
Casas-Solvas et al. “Synthesis of Nitrogen-Functionalized β-Cycloaltrins”, Journal of Organic Chemistry, 69(25), 8942-8945 (2004).
Kraus et al. “A homologous series of persubstituted cyclodextrin amino acids: The quest for tubular self-assembly”, European Journal of Organic Chemistry, (19), 4060-4069 (2004).
Sallas et al. “A practical synthesis of amphiphilic cyclodextrins fully substituted with sugar residues on the primary face”, Chemical Communications (Cambridge, United Kingdom) (5), 596-597(2004).
Mourtzis et al. “Influence of Host's Substitution on the Orientation of the Guest: Pseudo-rotaxanes of Charged Cyclodextrins with Methyl Orange in Solution”; Supramolecular Chemistry, 16(8), 587-593 (2004).
Heck et al. “Heptakis-6-(5-methylene-thioureido-5′-methyl-2,2′-bipyridy1)-β-cyclodextrin; synthesis and metal complexation study”; Tetrahedron Letters, 44(8), 1533-1536 (2003).
Heck et al. “New scaffolds for supramolecular chemistry: upper-rim fully tethered 5-methyleneureido-5′-methyl-2,2′-bipyridyl cyclodextrins”; Chemistry—A European Journal, 8(11), 2438-2445(2002).
Reddy et al. “An efficient protocol for

Affiliated with

Also associated with

Rating

β-Cyclodextrin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β-Cyclodextrin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-Cyclodextrin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4159256